TABLE I.
Age-Adjusted Incidence Rates of Lymphoma in the AYA (age 15–39 years) and adult (age > 39 years) patient populations
| AYA | Adult | ||||
|---|---|---|---|---|---|
| Lymphoma Subtypes | ICD-0–3 codes | N | Age-Adjusted Incidence Rate per 100,000 person-years (95% CI) |
N | Age-Adjusted Incidence Rate per 100,000 person- years (95% CI) |
| Hodgkin lymphoma | |||||
| Classical Hodgkin lymphoma | 9650–9655, 9663– 9667, 9661,9662 |
15451 | 3.44 (3.38–3.49) | 15249 | 2.82 (2.77–2.86) |
| Nodular lymphocyte predominant Hodgkin lymphoma |
9659 | 638 | 0.14 (0.13–0.16) | 949 | 0.17 (0.16–0.18) |
| Non-Hodgkin lymphoma, B-cell | |||||
| Precursor B-cell lymphoblastic leukaemia/lymphoma, NOS |
9727 (B), 9728, 9835(B), 9836, 9811 |
3176 | 0.71 (0.69–0.74) | 4336 | 0.79 (0.76–0.81) |
| Precursor B-cell lymphoblastic leukaemia/lymphoma, with recurrent genetic abnormalities |
9812–9818 | 110 | 0.025 (0.02–0.03) | 212 | 0.038 (0.03–0.04) |
| Chronic lymphocytic leukaemia/small lymphocytic lymphoma |
9670, 9823 | 617 | 0.15 (0.14–0.16) | 70785 | 13.19 (13.09–13.29) |
| Prolymphocytic leukaemia, B-cell | 9832 (B), 9833 | NA | 0.002 (0.001–0.004) | 296 | 0.056 (0.05–0.06) |
| Mantle cell lymphoma | 9673 | 86 | 0.021 (0.017–0.026) | 9453 | 1.752 (1.12–1.79) |
| Lymphoplasmacytic lymphoma, including Waldenstrom macroglobulinaemia |
9671, 9761 | 75 | 0.018 (0.014–0.022) | 7817 | 1.47(1.44–1.50) |
| DLBCL, NOS | 9684 (B), 9680 (excluding C44.0– 44.9, C49.9, C71.0– 71.9) |
6289 | 1.45 (1.41–1.49) | 73346 | 13.7 (13.6–13.8) |
| Primary DLBCL of the CNS | 9680 (C71.0–71.9) | 246 | 0.058 (0.051–0.065) | 3109 | 0.578 (0.56–0.60) |
| Primary cutaneous DLBCL, leg type | 9680 (C44.0–44.9) | 56 | 0.013 (0.010–0.017) | 1317 | 0.25 (0.23–0.26) |
| T-cell/histiocycte rich large B-cell lymphoma | 9688 | 54 | 0.012 (0.009–0.016) | 208 | 0.038 (0.033– 0.044) |
| Intravascular large B-cell lymphoma | 9712, 9680 (C49.9) | NA | 45 | 0.008 (0.006– 0.011) |
|
| ALK positive large B-cell lymphoma | 9737 | NA | 0.002 (0.001–0.003) | NA | 0.002 (0.001– 0.004) |
| Plasmablastic lymphoma | 9735 | 58 | 0.013 (0.010–0.017) | 267 | 0.048 (0.043–0.055) |
| Large B-cell lymphoma HHV8-associated multicentric Castleman disease |
9738 | NA | 0.002 (0.001–0.004) | 27 | 0.005 (0.003– 0.007) |
| Primary effusion lymphoma | 9678 | 25 | 0.006 (0.004–0.008) | 107 | 0.02 (0.016–0.024) |
| Primary mediastinal (thymic) large B-cell lymphoma |
9679 | 349 | 0.079 (0.071–0.88) | 220 | 0.041 (0.036– 0.047) |
| Burkitt lymphoma/leukaemia | 9687, 9826 | 1157 | 0.26 (0.25–0.28) | 2654 | 0.49 (0.47–0.51) |
| Marginal Zone lymphoma | 9689, 9699, 9764 | 1023 | 0.24 (0.22–0.25) | 22128 | 4.10 (4.05–4.16) |
| Follicular lymphoma | 9690, 9691, 9695, 9688 |
2095 | 0.5 (0.49–0.52) | 42497 | 7.78 (7.70–7.85) |
| Hairy cell leukaemia | 9940 | 307 | 0.075 (0.067–0.084) | 3402 | 0.62 (0.60–0.64) |
| Hairy cell leukaemia variant | 9591 (site 42.1–32.2) | 18 | 0.004 (0.002–0.007) | 1651 | 0.31 (0.30–0.33) |
| Plasma cell neoplasms | 9731, 9734, 9732, 9733 |
1129 | 0.27 (0.26–0.29) | 76200 | 14.17 (14.07–14.27) |
| B-cell lymphoid neoplasms, NOS | 9590 (B), 9591 (B), 9675 (B), 9820 (B), 9970 (B) |
880 | 0.20 (0.19–0.22) | 18328 | 3.73 (3.39–3.49) |
| Non-Hodgkin lymphoma, T/NK-cell | |||||
| Precursor T/NK-cell lymphoblastic leukaemia/lymphoma, NOS |
9727 (T), 9729, 9835(T), 9837 |
1277 | 0.28 (0.27–0.30) | 817 | 0.15 (0.14–0.16) |
| Mycosis Fungoides/Sezary syndrome | 9700, 9701 | 742 | 0.17 (0.16–0.18) | 4718 | 0.86 (0.84–0.89) |
| Peripheral T/NK-cell lymphoma | 9702, 9705, 9716, 9717, 9714, 9724, 9726, 9708, 9709 |
1595 | 0.37 (0.35–0.39) | 11019 | 2.04 (2.00–2.08) |
| Adult T-cell leukaemia/lymphoma | 9827 | 66 | 0.015 (0.012–0.019) | 385 | 0.071 (0.064– 0.079) |
| Extranodal NK/T-cell lymphoma, nasal type | 9719 | 206 | 0.047 (0.04–0.05) | 591 | 0.107 (0.099– 0.116) |
| T-cell large granular lymphocytic leukaemia | 9831 | NA | 0.003 (0.002–0.005) | 193 | 0.036 (0.031– 0.042) |
| T-cell prolymphocytic leukaemia | 9834, 9832(T) | NA | 0.003 (0.001–0.005) | 402 | 0.075 (0.067– 0.082) |
| Aggressive NK-cell leukaemia | 9948 | NA | 0.003 (0.002–0.006) | 88 | 0.016 (0.013–0.020) |
| Primary cutaneous CD30 + lymphoproliferative disorders |
9718 | 157 | 0.036 (0.31–0.42) | 950 | 0.17 (0.16–0.19) |
| T/NK-cell lymphoid neoplasms, NOS | 9591(T), 9590(T), 9684(T), 9820(T), 9970(T) |
63 | 0.014 (0.011–0.018) | 546 | 0.102 (0.093–0.110) |
AYA: adolescent and young adult; CI: confidence interval; DLBCL: diffuse large B cell lymphoma; HHV8: human herpes virus 8; ICD-0–3: International Classification of Diseases for Oncology, third edition; NA: not available, too few cases to be displayed; NK: Natural Killer; NOS: not otherwise specified